Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death.

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

Brazzi L;Montrucchio G;Sales G
2023-01-01

Abstract

Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death.
2023
52
2
355
376
https://academic.oup.com/ije/article/52/2/355/7059267
COVID-19; SARS-CoV-2; co-morbidities; cohort study; risk of death; symptoms; treatments
Kartsonaki, Christiana; Baillie, J Kenneth; Barrio, Noelia García; Baruch, Joaquín; Beane, Abigail; Blumberg, Lucille; Bozza, Fernando; Broadley, Tessa; Burrell, Aidan; Carson, Gail; Citarella, Barbara Wanjiru; Dagens, Andrew; Dankwa, Emmanuelle A; Donnelly, Christl A; Dunning, Jake; Elotmani, Loubna; Escher, Martina; Farshait, Nataly; Goffard, Jean-Christophe; Gonçalves, Bronner P; Hall, Matthew; Hashmi, Madiha; Sim Lim Heng, Benedict; Ho, Antonia; Jassat, Waasila; Pedrera Jiménez, Miguel; Laouenan, Cedric; Lissauer, Samantha; Martin-Loeches, Ignacio; Mentré, France; Merson, Laura; Morton, Ben; Munblit, Daniel; Nekliudov, Nikita A; Nichol, Alistair D; Singh Oinam, Budha Charan; Ong, David; Panda, Prasan Kumar; Petrovic, Michele; Pritchard, Mark G; Ramakrishnan, Nagarajan; Ramos, Grazielle Viana; Roger, Claire; Sandulescu, Oana; Semple, Malcolm G; Sharma, Pratima; Sigfrid, Louise; Somers, Emily C; Streinu-Cercel, Anca; Taccone, Fabio; Vecham, Pavan Kumar; Kumar Tirupakuzhi Vijayaraghavan, Bharath; Wei, Jia; Wils, Evert-Jan; Ci Wong, Xin; Horby, Peter; Rojek, Amanda; Olliaro, Piero L; Brazzi L; Montrucchio G; Sales G
File in questo prodotto:
File Dimensione Formato  
228 - 2023 Characteristics and outcome - Kartonaski.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.38 MB
Formato Adobe PDF
1.38 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1900432
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact